TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24629408

Group type: EXPERIMENTAL
Intervention: T1W (type 1 diabetes with neuropathy)
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: T1WO (type 1 diabetes without neuropathy)
Number of subjects: 396

Group type: COMPARATOR
Intervention: Controls (without diabetes or neuropathy)
Number of subjects: 396
Study: 22344576

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400 mg every 4 weeks plus MTX
Number of subjects: 247

Group type: COMPARATOR
Intervention: Placebo plus MTX
Number of subjects: 247
Study: 19643620

Group type: EXPERIMENTAL
Intervention: Dynamic blood-flow control during CPB
Number of subjects: 100

Group type: COMPARATOR
Intervention: Static blood-flow control during CPB
Number of subjects: 100
Study: 17957910

Group type: EXPERIMENTAL
Intervention: Pueraria mirifica (PM) 50 mg daily, Group A
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conjugated equine estrogen (CEE) 0.625 mg daily with/without medroxyprogesterone acetate (MPA) 2.5 mg, Group B
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both PM and CEE with/without MPA
Number of subjects: 60
Study: 16360062

Group type: EXPERIMENTAL
Intervention: Sequential cardiac resynchronization therapy (CRT) for six months
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Sequential cardiac resynchronization therapy (CRT)
Number of subjects: 422

Group type: COMPARATOR
Intervention: Simultaneous cardiac resynchronization therapy (CRT)
Number of subjects: 422
Study: 12463580

Group type: EXPERIMENTAL
Intervention: Neuraxial anesthesia with selective factor Xa inhibitor fondaparinux
Number of subjects: 0

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 0
Study: 10438081

Group type: EXPERIMENTAL
Intervention: One‐to‐one nurse labor support
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual intrapartum nursing care
Number of subjects: 100
Study: 7503052

Group type: EXPERIMENTAL
Intervention: Personal air monitor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Urine cotinine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Questionnaire
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-report
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Air nicotine
Number of subjects: 0
Study: 2338698

Group type: COMPARATOR
Intervention: Atenolol 100 mg per day (n = 17)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Nitrendipine 20 mg daily (n = 18)
Number of subjects: 35
Study: 6102360

Group type: EXPERIMENTAL
Intervention: Flunitrazepam (1 mg and 2 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31136460

Group type: EXPERIMENTAL
Intervention: Strict posturing and bilateral patching overnight (Treatment A)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Posturing alone (Treatment B)
Number of subjects: 80
Study: 31634001

Group type: EXPERIMENTAL
Intervention: Jingshu Granules
Number of subjects: 480

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study: 28681742

Group type: EXPERIMENTAL
Intervention: Sensory-level electrical stimulation (SES) applied to bilateral masseter muscles
Number of subjects: 98

Group type: COMPARATOR
Intervention: Sham group (control)
Number of subjects: 98
Study: 26525849

Group type: EXPERIMENTAL
Intervention: Tobacco-heating cigarettes
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Snus
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Ultra-low machine yield tobacco-burning cigarettes
Number of subjects: 150
Study: 25019968

Group type: EXPERIMENTAL
Intervention: Endoscopic flushing with pronase (50 mL of water, pronase, sodium bicarbonate, and DMPS)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Endoscopic flushing with water and dimethylpolysiloxane (DMPS; control group)
Number of subjects: 198
Study: 22832859

Group type: EXPERIMENTAL
Intervention: Cannabidiol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amisulpride (Control)
Number of subjects: 0
Study: 19236805

Group type: EXPERIMENTAL
Intervention: Multiple-phase RIAC (preoperative combined with postoperative RIAC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Postoperative RIAC
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Multiple-phase RIAC
Number of subjects: 100
Study: 17765048

Group type: EXPERIMENTAL
Intervention: Short-course antibiotic regimens (7 days or less)
Number of subjects: 2796

Group type: COMPARATOR
Intervention: Extended-course antibiotic regimens (>7 days)
Number of subjects: 2796
Study: 15666519

Group type: EXPERIMENTAL
Intervention: Preoperative shaving of the pubic region
Number of subjects: 300

Group type: COMPARATOR
Intervention: No preoperative shaving of the pubic region
Number of subjects: 300
Study: 12351249

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion at 0.83 micro g. kg(‐1). min(‐1) (Group R)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Fentanyl bolus, small dose, at 12 micro g/kg (Group FLD)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Fentanyl bolus, moderate dose, at 24 micro g/kg (Group FMD)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Remifentanil (Group R) compared to Fentanyl (Group FLD)
Number of subjects: 77
Study: 9832574

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (40 parts per million)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional treatment (control group)
Number of subjects: 24
Study: 8137928

Group type: EXPERIMENTAL
Intervention: L-carnitine (2 g orally)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 2733576

Group type: EXPERIMENTAL
Intervention: 6% glucose solution
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 6% sucrose solution
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 6% fructose solution
Number of subjects: 12
Study: 786825

Group type: EXPERIMENTAL
Intervention: High-dose neurotropic vitamins (Neurotrat forte)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Analgesic treatment
Number of subjects: 0
Study: 31733182

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (10 mg) plus aspirin (75 to 100 mg) once daily
Number of subjects: 231

Group type: COMPARATOR
Intervention: Clopidogrel (75 mg) plus aspirin (75 to 100 mg) once daily
Number of subjects: 231
Study: 30566230

Group type: EXPERIMENTAL
Intervention: CPX-351
Number of subjects: 0

Group type: COMPARATOR
Intervention: 7 + 3 control group
Number of subjects: 0
Study: 28222553

Group type: EXPERIMENTAL
Intervention: Dual-afferent sensory input (DASI) group underwent ETFES with action observation training for 4 weeks (20 min/d, 5 d/wk)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Functional electric stimulation (FES) in control group for the same duration
Number of subjects: 18
Study: 26223668

Group type: EXPERIMENTAL
Intervention: Total mesorectal excision (TME) without pretreatment
Number of subjects: 560

Group type: COMPARATOR
Intervention: Neoadjuvant radiochemotherapy
Number of subjects: 560
Study: 23025465

Group type: EXPERIMENTAL
Intervention: narrative message (personal testimonial)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: non‐narrative cognitive message (factual risk information using cognitive‐laden words)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: non‐narrative affective message (factual risk information using affective‐laden words)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: narrative message
Number of subjects: 233
Study: 21725249

Group type: EXPERIMENTAL
Intervention: couple-based risk reduction
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: individual-based HIV risk reduction
Number of subjects: 564

Group type: COMPARATOR
Intervention: couple-based wellness promotion
Number of subjects: 564
Study: 20329690

Group type: EXPERIMENTAL
Intervention: Levonorgestrel regimen (0.75 mg taken twice in 12-hour intervals within 72 hours after unprotected intercourse)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Yuzpe method (two HD contraceptive pills)
Number of subjects: 122
Study: 16505658

Group type: EXPERIMENTAL
Intervention: Norepinephrine (0.052+/‐0.009 microg/kg/min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Phenylephrine (0.50+/‐0.22 microg/kg/min)
Number of subjects: 10
Study: 15047681

Group type: EXPERIMENTAL
Intervention: Tomato puree supplementation (96 g/day for three weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Avoidance of tomato-product-rich foods for three weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tomato puree supplementation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Plasma total antioxidant capacity
Number of subjects: 20
Study: 11265439

Group type: EXPERIMENTAL
Intervention: Touch distraction
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Bubble-blowing distraction
Number of subjects: 105

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 105
Study: 9306898

Group type: EXPERIMENTAL
Intervention: Podophyllin 0.5%
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Podophyllin 2.0%
Number of subjects: 315

Group type: COMPARATOR
Intervention: Podophyllotoxin 0.5%
Number of subjects: 315
Study: 8392150

Group type: EXPERIMENTAL
Intervention: Sumatriptan (SC, 6 mg; three attacks)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (one attack)
Number of subjects: 120
Study: 3310570

Group type: EXPERIMENTAL
Intervention: Antihypertensive drug therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta blocker
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biofeedback relaxation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Control of smoking and serum cholesterol
Number of subjects: 0
Study: 30384381

Group type: EXPERIMENTAL
Intervention: Genotype-guided treatment allocation (G‐allele carriers receiving naltrexone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (random treatment allocation to acamprosate or naltrexone)
Number of subjects: 0
Study: 27743738

Group type: EXPERIMENTAL
Intervention: Uterine Serous Carcinoma (USC)
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: Clear Cell Carcinoma (CC)
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: Carcinosarcoma (CS)
Number of subjects: 753

Group type: COMPARATOR
Intervention: Grade 3 Endometrioid Adenocarcinoma (ENDO)
Number of subjects: 753
Study: 24614165

Group type: EXPERIMENTAL
Intervention: First-line ART regimens including zidovudine or stavudine plus lamivudine, plus nevirapine or efavirenz
Number of subjects: 321

Group type: COMPARATOR
Intervention: Patients who experienced severe adverse drug reactions
Number of subjects: 321
Study: 22471125

Group type: EXPERIMENTAL
Intervention: Acupuncture-medication group (Baihui (GV 20) and Fengchi (GB 20) acupoints)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional treatment group (Nimodipine)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Acupuncture-medication group
Number of subjects: 60
Study: 19996728

Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study: 19167590

Group type: COMPARATOR
Intervention: Short-term danazol treatment (200 mg/d for 4 weeks)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Long-term danazol treatment (mean dose of 170 mg/d for >2 years)
Number of subjects: 15
Study: 16920183

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) session
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard care (advice/education)
Number of subjects: 56
Study: 15500196

Group type: EXPERIMENTAL
Intervention: benidipine hydrochloride (4 mg/day)
Number of subjects: 85

Group type: COMPARATOR
Intervention: amlodipine (5-7.5 mg/day)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: benidipine hydrochloride (4-8 mg/day)
Number of subjects: 85

Group type: COMPARATOR
Intervention: amlodipine
Number of subjects: 85
Study: 10934910

Group type: EXPERIMENTAL
Intervention: Instructions to suppress negative emotion
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Instructions to enhance negative emotion
Number of subjects: 48
Study: 9056051

Group type: EXPERIMENTAL
Intervention: Lazabemide 100 mg twice daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lazabemide 350 mg twice daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lazabemide (100-350 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lazabemide (single and multiple doses)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lazabemide (multiple dosing)
Number of subjects: 30
Study: 8448921

Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis fluid at pH 7 (D7)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Peritoneal dialysis fluid at pH 5 (D5)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis fluid with 3.86% glucose (D386)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Peritoneal dialysis fluid with 1.36% glucose (D136)
Number of subjects: 16
Study: 3021189

Group type: EXPERIMENTAL
Intervention: Aspirin 10 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Aspirin 30 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Aspirin 600 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Aspirin (in vivo)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (Thrombin)
Number of subjects: 8
Study: 30398957

Group type: EXPERIMENTAL
Intervention: Hydrolyzed beef protein (PRO, n=8)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Nonprotein isoenergetic carbohydrate (CHO, n=8)
Number of subjects: 16
Study: 29629507

Group type: EXPERIMENTAL
Intervention: ProSAAF program
Number of subjects: 346

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 346
Study: 26338075

Group type: COMPARATOR
Intervention: pterygomaxillary dysjunction + saline
Number of subjects: 200

Group type: COMPARATOR
Intervention: tuberosity separation + saline
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: pterygomaxillary dysjunction + tranexamic acid
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: tuberosity separation + tranexamic acid
Number of subjects: 200
Study: 24837466

Group type: EXPERIMENTAL
Intervention: e13a2
Number of subjects: 1105

Group type: EXPERIMENTAL
Intervention: e14a2
Number of subjects: 1105

Group type: COMPARATOR
Intervention: Imatinib treatment
Number of subjects: 1105
Study: 22092512

Group type: EXPERIMENTAL
Intervention: Mandibular two-implant overdentures (IODs)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Conventional complete dentures (CDs)
Number of subjects: 172
Study: 20528908

Group type: EXPERIMENTAL
Intervention: Bortezomib treatment (four cycles, initially as monotherapy, then combined with glucocorticoid from cycle two to four)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bortezomib treatment with glucocorticoid
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bortezomib in vitro
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Glucocorticoid treatment in vitro
Number of subjects: 20
Study: 18271279

Group type: EXPERIMENTAL
Intervention: Calcium-fortified orange beverage
Number of subjects: 10

Group type: COMPARATOR
Intervention: Milk
Number of subjects: 10
Study: 15101020

Group type: EXPERIMENTAL
Intervention: Warfarin (target INR 2.5-3.0)
Number of subjects: 1587

Group type: COMPARATOR
Intervention: Aspirin 162 mg
Number of subjects: 1587

Group type: COMPARATOR
Intervention: Clopidogrel 75 mg
Number of subjects: 1587

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 1587

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 1587

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 1587
Study: 12234946

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg for 14 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 9836113

Group type: EXPERIMENTAL
Intervention: Complete alcohol withdrawal after 7 and 14 days
Number of subjects: 51
Study: 7917697

Group type: EXPERIMENTAL
Intervention: VVIR pacing mode
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: VVI 85 pacing mode
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Activity pacemakers
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Dual sensor pacemakers
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control population
Number of subjects: 29
Study: 2510530

Group type: EXPERIMENTAL
Intervention: Cefotaxime (1 g single preoperative dose)
Number of subjects: 1451

Group type: COMPARATOR
Intervention: Cefoxitin (four 2-g doses)
Number of subjects: 1451
Study: 4838915

Group type: EXPERIMENTAL
Intervention: Chocolate
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 30914169

Group type: EXPERIMENTAL
Intervention: Adolescent girls' agency
Number of subjects: 3186
Study: 27873516

Group type: EXPERIMENTAL
Intervention: Standard dose EC‐MPS with low dose CsA
Number of subjects: 140

Group type: COMPARATOR
Intervention: Standard dose CsA with low dose EC‐MPS
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 140
Study: 25928131

Group type: EXPERIMENTAL
Intervention: Integrative treatment (IT)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Therapeutic acupuncture (TA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional treatment (CT)
Number of subjects: 120
Study: 23867209

Group type: EXPERIMENTAL
Intervention: Synbiotic therapy (7 days preoperative and 10 days postoperative)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group without synbiotic therapy
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Synbiotic therapy
Number of subjects: 48
Study: 22089773

Group type: EXPERIMENTAL
Intervention: L-Carnitine supplementation (1 g/dose, intravenously three times a week after each HD session)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (no L-Carnitine supplementation)
Number of subjects: 35
Study: 19933081

Group type: EXPERIMENTAL
Intervention: Liposomal doxorubicin 40 mg/m(2) intravenously every 28 days
Number of subjects: 102

Group type: COMPARATOR
Intervention: Weekly docetaxel 36 mg/m(2) intravenously days 1, 8, and 15, repeated every 28 days
Number of subjects: 102
Study: 17086087

Group type: EXPERIMENTAL
Intervention: Conventional fitting procedure
Number of subjects: 18

Group type: COMPARATOR
Intervention: ECAP based fitting procedure
Number of subjects: 18
Study: 15001930

Group type: EXPERIMENTAL
Intervention: Dexamethasone for 3 days
Number of subjects: 59
Study: 11316896

Group type: EXPERIMENTAL
Intervention: Whole Blood (WB)
Number of subjects: 24

Group type: COMPARATOR
Intervention: RBCs and FFP (RCP)
Number of subjects: 24
Study: 9374563

Group type: EXPERIMENTAL
Intervention: Ibuprofen 5 mg/kg
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Ibuprofen 10 mg/kg
Number of subjects: 285

Group type: COMPARATOR
Intervention: Acetaminophen 12 mg/kg
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Children hospitalized with dehydration
Number of subjects: 285
Study: 7955970

Group type: EXPERIMENTAL
Intervention: Mixed meal (42 kJ, kg-1 lean body mass) during pregnancy
Number of subjects: 10

Group type: COMPARATOR
Intervention: Resting energy expenditure during pregnancy
Number of subjects: 10

Group type: COMPARATOR
Intervention: Resting energy expenditure after pregnancy
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Postprandial thermogenesis after pregnancy
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Insulin resistance during pregnancy (0.05 U kg-1 intravenously)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Insulin resistance after pregnancy (0.05 U kg-1 intravenously)
Number of subjects: 10
Study: 3790639

Group type: EXPERIMENTAL
Intervention: Naltrexone, 300 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31206613

Group type: EXPERIMENTAL
Intervention: N-acetyl-cysteine (NAC) 50 mg/kg IV plus 500 mg oral twice per day for 3 months
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard of care only
Number of subjects: 42
Study: 28729158

Group type: EXPERIMENTAL
Intervention: Dolutegravir plus abacavir and lamivudine (single-tablet regimen)
Number of subjects: 499

Group type: COMPARATOR
Intervention: Ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine (three-tablet combination)
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Dolutegravir plus abacavir and lamivudine
Number of subjects: 499

Group type: COMPARATOR
Intervention: Ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine
Number of subjects: 499
Study: 25908245

Group type: EXPERIMENTAL
Intervention: Piezosurgery
Number of subjects: 37

Group type: COMPARATOR
Intervention: Conventional saw
Number of subjects: 37
Study: 23732643

Group type: EXPERIMENTAL
Intervention: 4 weeks of supervised resistive exercise (for young individuals)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 4 weeks of supervised resistive exercise (for older individuals)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 4 weeks of supervised resistive exercise (for both groups)
Number of subjects: 20
Study: 21823280

Group type: EXPERIMENTAL
Intervention: Acupoint catgut embedding combined vessel pricking therapy (group A)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Oral administration of Sulfasalazine (SASP) (group B)
Number of subjects: 86
Study: 20082923

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 1616

Group type: COMPARATOR
Intervention: Pravastatin 40 mg
Number of subjects: 1616
Study: 16768632

Group type: EXPERIMENTAL
Intervention: Extended-release dexmethylphenidate (d-MPH-ER) 20 mg/day
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 12781282

Group type: EXPERIMENTAL
Intervention: Hydrogel intraocular lens (IOL)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Silicone intraocular lens (IOL)
Number of subjects: 37
Study: 11152929

Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Tablet containing 1-mg folic acid, 1-mg B12, and 25-mg B6
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Tablet containing 2.5-mg folic acid, 1-mg B12, and 25-mg B6
Number of subjects: 50
Study: 9329288

Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 394

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 394
Study: 8378772

Group type: EXPERIMENTAL
Intervention: Oral administration of chicken type II collagen for 3 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60